Pharmaceutical News

RSS

Ranbaxy to implement Instem's Provantis preclinical software suite at Gurgaon R&D center in India

Instem, a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that Ranbaxy Laboratories Limited (Ranbaxy) has purchased the Provantis preclinical software suite to automate laboratory processes at their R&D Headquarters in Gurgaon, India.

9 May 2014

Researchers discover new class of drugs to treat nystagmus eye condition

In another example of serendipity advancing scientific research, investigators have discovered a new class of drugs to treat an eye condition called nystagmus.

9 May 2014

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.

9 May 2014

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

9 May 2014

Antipsychotic medication reduces violent crime rates

People who use antipsychotic medication (such as clozapine or risperidone) to treat psychiatric illness are nearly half as likely to commit a violent crime compared to when they are not using such medication, according to new results published in The Lancet.

8 May 2014

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

8 May 2014

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.

8 May 2014

Shuganjieyu capsule reverses depressive behaviors by increasing brain-derived neurotrophic factor

Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Administration of China since 2008.

8 May 2014

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.

8 May 2014

Form of baclofen works better at treating narcolepsy

Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice.

8 May 2014

Researchers create universal flu vaccine

Researchers at the University of Texas Medical Branch are working to create a universal flu vaccine - one that could eliminate the need for an annual flu shot.

8 May 2014

Systagenix introduces hydro-active dressing in UK and Germany

Systagenix announced today the launch of BIOSORB™, a hydro-active dressing containing superabsorbent fluid-retaining polymers.

7 May 2014

Scientists develop gel based eye fluid to help stabilize eye after retinal detachment surgery

In an effort to avoid serious side effects suffered after surgery to repair retinal detachment, vision scientists have developed a new product to help stabilize the eye while it heals.

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.

6 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.

6 May 2014

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life.

6 May 2014

Rates of infant immunization with pertussis-containing vaccine do not increase with epidemic

Conventional wisdom holds that when the risk of catching a disease is high, people are more likely to get vaccinated to protect themselves.

6 May 2014

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.

6 May 2014

Pharmaceutical News

Ranbaxy to implement Instem's Provantis preclinical software suite at Gurgaon R&D center in India

Researchers discover new class of drugs to treat nystagmus eye condition

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Antipsychotic medication reduces violent crime rates

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Shuganjieyu capsule reverses depressive behaviors by increasing brain-derived neurotrophic factor

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Form of baclofen works better at treating narcolepsy

Researchers create universal flu vaccine

Systagenix introduces hydro-active dressing in UK and Germany

Scientists develop gel based eye fluid to help stabilize eye after retinal detachment surgery

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

FDA accepts Merck's MK-3475 BLA for review

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Rates of infant immunization with pertussis-containing vaccine do not increase with epidemic

Teva's SYNRIBO for injection receives FDA approval for home administration

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News